Prevalence of hepatitis C infection in a large urban hospital-based sample of individuals with spinal cord injury

Archives of Physical Medicine and Rehabilitation

Volumn 83, Issue 11, 2002, Pages 1620-1623

  Fong, Tse Ling ^a,b   Adkins, Rodney H ^a   Govindarajan, Sugantha ^a,b   Post, Susan ^c   Waters, Robert L ^a,b  

^a Rancho Los Amigos National Rehabilitation Hospital   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c BURNS AND ALLEN RESEARCH INSTITUTE   (United States)

Author keywords

Hepatitis B virus; Liver; Rehabilitation; Spinal cord injuries

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; HEPATITIS C ANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CHRONIC DISEASE; COHORT ANALYSIS; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; INFECTIOUS COMPLICATION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PHYSICAL EXAMINATION; REHABILITATION CENTER; RETROSPECTIVE STUDY; SEROPREVALENCE; SPINAL CORD INJURY; URBAN AREA;

EID: 0036845095     PISSN: 00039993     EISSN: None     Source Type: Journal    
DOI: 10.1053/apmr.2002.00000     Document Type: Article

References (30)

1. Go BK, DeVivo MJ, Richards JS. In: Stover SL, DeLisa JA, Whiteneck GG, editors. Spinal Cord Injury: Clinical Outcomes from the Model Systems. Gaithersburg (MD): Aspen; 1995. p 21-51.
2. Waters RL, Meyer PR Jr, Adkins RH, Felton D. Emergency, acute, and surgical management of spinal trauma. Arch Phys Med Rehabil 1999;80:1383-90.
3. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-6.
4. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histological follow-up of chronic posttransfusion hepatitis. Hepatology 1991;14:969-74.
5. Rosman AS, Chinigo AS, Spungen AM, Drexler HJ, Bauman WA. Viral hepatitis in patients with spinal cord injury is explained by known risk factors. J Spinal Cord Med 1998;21:25-31.
6. Alter MJ, Kruszon-Morgan D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62.
7. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. N Engl J Med 1996;334:1685-90.
8. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998;47(RR-19):1-39.
9. Fong T-L, Lee SR, Kim J, et al. Prevalence of hepatitis G virus among intravenous drug users in Los Angeles. Clin Infect Dis 1997;25:487-8.
10. Wilkins JN, Shaner AL, Patterson CM, Setoda D, Gorelick D. Discrepancies between patient report, clinical assessment, and urine analysis in psychiatric patients during inpatient admission. Psychopharmacol Bull 1991;27:149-54.
11. Stevens CE, Aach RD, Hollinger FB, et al. Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients. An analysis of the Transfusion-Transmitted Virus Study. Ann Intern Med 1984;101:733-8.
12. Mosley JW, Huang W, Stram DO, et al. Donor levels of serum alanine aminotransferase activity and antibody to hepatitis B core antigen associated with recipient hepatitis C and non-B, non-C outcomes. Transfusion 1996;36:776-81.
13. Jilg W, Sieger E, Zachoval R, Schatzl H. Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: High percentage of carriers of hepatitis B and C virus. J Hepatol 1995;23:14-20.
14. Gretch DR. Diagnostic tests for hepatitis C. Hepatology 1997;26 Suppl 1:43S-7S.
15. Fong T-L, Lee SR, Briggs WK, et al. Clinical significance of hepatitis C viral RNA status and its correlation to antibodies to structural HCV antigens in anti-HCV reactive patients with normal liver tests. J Med Virol 1996;49:253-8.
16. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999:340:1228-33.
17. Wiese M, Berr F, Lafranz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: A 20-year multicenter study. Hepatology 2000;32:91-6.
18. Persico M, Persico E, Suozzo R, et al. Natural history of hepatitis C carriers with persistently normal aminotransferase levels. Gastroenterology 2000;118:760-4.
19. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12:671-5.
20. Wiley TE, McCarthy M, Briede L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998;22:805-9.
21. Poynard T, Bedossa M, Opolon P. Natural history of fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-32.
22. Fattovich G, Giustina G. Degos F, et al. Morbidity and mortality in compensated cirrhosis, type C: A retrospective follow-up study of 384 patients. Gastroenterology 1997:112:463-72.
23. National Institutes of Health Consensus Development Conference Panel Statement. Management of hepatitis C. Hepatology 1997;26 Suppl 1:2S-10S.
24. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
25. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72.
26. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001;358:958-65.
27. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997;26 Suppl 1:112S-21S.
28. Whiteneck GG, Charlifue SW, Frankel HL, et al. Mortality, morbidity and psychosocial outcomes of persons with spinal cord injured more than 20 years ago. Paraplegia 1992;30:617-30.
29. DeVito MJ, Black KJ, Stover SL. Causes of death during the first 12 years after spinal cord injury. Arch Phys Med Rehabil 1993;74:248-54.
30. Fuhrer MJ, Rintala DH, Hart KA, Clearman R, Young ME. Depressive symptomatology in persons with spinal cord injury who reside in the community. Arch Phys Med Rehabil 1993;74:255-60.